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Abstract 
Involvement of the central nervous system (CNS) is rarely described in malignant mixed 
Müllerian tumors (MMMT). Only 4 intracranial and 2 spinal cases have been published to 
date. Here we report two more cases with heterogeneous clinical, radiological and 
pathological features and summarize the available contemporary literature.  
One patient presented with aphasia due to an intraaxial contrast enhanced left temporal lesion 
with marked perifocal edema. After surgical resection, histology showed collections of small 
uniform tumor cells embedded in a myxoid matrix and compartmentalized by connective 
tissue septations, consistent with a MMMT. The other patient presented with 
trigeminal/tongue hypesthesia and double vision accompanied by left radiculopathy and 
paresis. MRI revealed an extraaxial lesion at the petrous tip with mild perifocal edema and 
multiple small intradural contrast enhancing lesions of the conus and cauda medullaris. 
Histological examination of the intracranial lesion showed a mainly papillary architecture, 
also consistent with MMMT. The spinal lesions were not excised and both patients received 
adjuvant radiochemotherapy. The first patient died 3 months and the second patient 12 
months after surgery. 
As illustrated by the heterogeneous clinicopathological features of our 2 cases as well as the 
reviewed literature, CNS metastasis of MMMT are diagnostically challenging, show a 
variable outcome, and thus require individualized treatment. In the present cases and CNS 
metastases reported to date, a higher histological ratio of sarcomatous to epithelial 
components portends a worse outcome.  
 
Introduction 
Malignant mixed Müllerian tumor (MMMT) represents a subtype of uterine sarcomas 
composed of malignant admixed epithelial and mesenchymal sarcomatous elements.[1] 
MMMT typically occurs in postmenopausal women, rarely in patients under 40 years of age.   
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Of further note, MMMT is one of the most malignant gynecologic tumors with an overall 5 
year survival of approximately 30%.[1]. Prognostic indicators include the depth of myometrial 
invasion and the surgical stage.  Recurrent and / or metastatic tumors can be exclusively 
sarcomatous, carcinomatous or mixed. 
The origin of this rare carcinosarcoma is controversial, but suggested to be stem cells that 
divergently differentiate into components that resemble Müllerian epithelium and 
mesenchymal tissues found in the uterus.[2] 
Surgical resection is generally the primary therapy of malignant mesenchymal uterine tumors. 
Patients who undergo surgery initially show a better prognosis in comparison to patients who 
are  solely treated with radiotherapy.[3] Studies demonstrate  that the removal of pelvic and 
paraaortal lymphnodes further improve the outcome of patients.[4]The 5-year survival rate for 
nodal negative patients is 64,2%, while it is only 26% for nodal positive patients.[5]  
Therefore, lymphadenectomy should be part of the primary operation. Regardless of the nodal 
state, adjuvant radiotherapy does not increase the survival rate.[4]Nevertheless, a reduction of 
the local pelvic recurrence rate after radiotherapy ranges from 48% to 28%. Adjuvant 
chemotherapy did not improve survival; however, palliative chemotherapy  in patients with 
metastasis or with recurrence significantly extends survival.[6] Patients in advanced disease 
stages respond to a therapy with Carboplatin and Paclitaxel in 60%, while 55% show  a 
recurrence of MMMT.[7] Combined chemotherapy with paclitaxel, carboplatin and liposomal 
pegylated doxorubicin administered to patients with advanced and recurred MMMT results in 
complete response in 34% and a partial response in 28%. The median overall survival is 16.4 
month.[8]  
Although only limited data are available regarding metastatic tumors in MMMT, the relative 
proportion of the sarcomatous component in the primary tumor is thought to be predictive of 
increased aggressiveness.[9]. Local progression with lymphatic and hematogenous metastasis 
is common; however, central nervous system (CNS) involvement is rare. To our knowledge, 
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there are only 4 metastatic intracranial and 2 spinal cases reported in the literature.[2, 10-14] 
Here we report two additional CNS metastases of MMMT and summarize the literature to 
further analyze risk factors that predict patient outcome. 
 
Case Presentation 
Case 1  
This 55 year-old female patient was initially diagnosed with MMMT and underwent 
hysterectomy with adnexectomy. At the time of diagnosis there was no evidence of metastasis 
at staging including brain MRI and the patient received adjuvant chemotherapy with 
carboplatin and paclitaxel. Three months after the second chemotherapy cycle, the patient 
developed aphasia and clinical signs of increased intracranial pressure including headache and 
dizziness. Epileptic events were not reported and the electroencephalogram was normal. 
Cranial magnetic resonance imaging (MRI) showed an intraaxial, left temporal contrast 
enhancing lesion (29x35x32mm) with massive perifocal edema and two small left frontal 
lesions (Figure 1). Antiedema therapy with steroids was started followed by craniotomy and 
complete resection of the left temporal lesion. Histology revealed a metastasis of the primary 
MMMT composed of collections of small, monomorphic tumor cells embedded in a myxoid 
matrix and compartmentalized by connective tissue septations. In some areas, the histological 
pattern of the brain metastasis resembled the primary tumor within the uterus (Figure 2). The 
aphasia improved after surgery and a third cycle of the adjuvant chemotherapy was applied. 
Postoperative MRI showed a complete resection of the lesion with persistent edema of the left 
hemisphere (Figure 1). Cortisone was continued and after 2 weeks of neurorehabilitation, 
adjuvant whole brain radiation was started. However, the patient deteriorated during radiation, 
suffering from vigilance problems and a general weakening. Therefore, therapy was stopped 
at the request of the patient. The patient died 3 months after the neurosurgical intervention.  
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Case 2 
This 66 year-old patient was diagnosed with MMMT and treated with hysterectomy and 
pelvic lymphadenectomy followed by adjuvant radiotherapy of the pelvis (total of 50.4 Gy) 
and chemotherapy with a total of 120mg epirubicin and 100mg cisplatin. Initial staging did 
not reveal any metastatic lesions (pT2b pN1 (4/17) M0 G3 R0). Fourteen months after 
diagnosis, the patient described trigeminal and tongue hypesthesias as well as double vision. 
In addition, examination showed left-sided radiculopathy with M3 paresis of the left leg 
without evidence of cauda equina involvement. MRI revealed an extraaxial lesion at the 
petrous tip in the cerebello-pontine angle with mild perifocal edema and multiple small 
intradural lumbar lesions along the cauda and conus medullaris (Figure 2). Histological 
examination after resection of the intracranial lesion showed a mainly papillary epithelial 
architecture consistent with a MMT (Figure 3). Postoperative CT showed a complete 
resection of the lesion (Figure 2). The multiple spinal lesions were not excised. 
Postoperatively, the patient received adjuvant radiotherapy of the thoracolumbar spine (BWK 
11 to LWK 5) with 30 Gy plus whole brain to a total of 30 Gy. After neurorehabilitation, 
preoperative cranial nerve symptoms resolved; however, the patient died one year after 
neurosurgical resection due to primary pelvic tumor progression.   
 
Discussion 
Uterine sarcomas are rare neoplasms that commonly show local and extraabdominal 
metastasis; however, the incidence of CNS metastases is very low. The likelihood of 
metastasis of MMMTs seems to be associated with stage of the disease, deep myometrial 
invasion, cervical tumor extension and positive retroperitoneal lymphnodes.[1] So far it 
remains unclear, which element of MMMTs is more likely to determine the metastasis. While 
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some studies favor the epithelial component to be more predictive of aggressive behavior,[15] 
other studies indicate that the sarcomatous component is associated with a poorer outcome.[2] 
A study by Silverberg an colleagues comparing primary MMT lesions with metastases found 
high-grade, serous, and clear cell carcinomatous components of the primary tumor to be 
associated with a higher frequency of metastases suggesting an aggressive/invasive behavior 
of the epithelial component.[16]  
According to our literature review, only one case was reported that demonstrated a 
composition similar to the primary tumor.[10] In all other reports with CNS metastasis, 
details a comparison of the proportion of the epithelial and sarcomatous components in the 
metastasis and primary tumor was not reported.[2, 11, 13, 14] Table 1 summarizes the 
literature with regards to the histopathological composition of the cerebral metastasis and 
highlights the variability of the sarcomatous or epithelial components. This is also reflected in 
the histopathological findings of our two cases, including one predominantly sarcomatous and 
another with predominanty epithelial composition. Interestingly, the life expectancy of 
patients with sarcomatous CNS metastases was clearly lower with a mean overall survival of 
2.5 months (range 1-3), compared to patients with metastases lacking a mainly sarcomatous 
composition (n=3, mean overall survival of 28.3 months, range 24-36) (Table 1). Even though 
a complete resection was performed in patients with sarcomatous metastasis, life expectancy 
still remained very low, as illustrated by our case 1 and the case reported by Kim et al.[14] 
Additionally, the time between primary MMMT diagnosis to CNS metastasis was lower in the 
sarcomatous CNS metastasis group with a time of 0, 0, 1 and 3 months and 7 and 14 months 
in the epithelial group.[2, 10, 11, 14] .Of note, a single patient without a predominant 
composition was diagnosed with a CNS metastasis 6 months after primary diagnosis.[13] 
Besides the heterogeneous histopathological findings, the clinical presentations and 
radiological findings vary greatly. For example, one of our patients showed an intradural 
cranial metastasis and the other an extradural cranial and intradural spinal metastasis. Cormio 
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et al. described a patient with multiple intracranial intradural lesions in addition to epidural 
spinal occurence.[11] Another patient from Stienen et al. presented with a spinal intradural, 
intramedullary symptomatic lesion, without an intracranial localization.[13] Therefore, it is 
important to report and collect more cases of this rare entity to acquire more accurate 
prognostic data to direct the development of future therapeutic strategies.  
 
Conclusion 
Despite surgical intervention and multimodal therapy, the prognosis of patients with MMMTs 
remains poor. Although CNS metastases from MMMTs are extremely rare, surgery is 
recommended for symptomatic lesions. Our cases and the scarce literature indicate that 
overall survival for patients with predominantly sarcomatous metastatic tumors is lower than 
for those in patients with predominantly epithelial tumor composition.  
 
 
 
Figure / Table Legend 
Figure 1: Corresponding images for case 1 (55yo female): Preoperative MRI T1 with contrast 
in coronal, axial and sagittal planes (A-C) and axial T2 (D) of the intraaxial, left temporal 
contrast enhancing lesion (29x35x32mm) lesion. Arrows in E show the two small left frontal 
lesions in T1 axial planes with contrast. F: Intraoperative high-frequency ultrasound (Real-
time L15-7 intraoperative probe, iU22 Ultrasound System, Philips, Bothell, USA) shows edge 
of craniotomy (*), solide (**) and cystic (***) tumor parts. Postoperative T1 with contrast in 
coronal and axial planes (G, H) showed complete resection of the lesion. 
 
Figure 2: Corresponding images for case 2 (66yo female): Preoperative MRI T1 with contrast 
in axial and coronal planes (A, B) and axial T2 (C) of the extraaxial lesion at the petrous tip in 
the cerebello-pontine angle. Postoperative CT in axial plane with contrast showed complete 
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resection (D). Lumbar MRI in sagittal T2 (E) and in T1 with contrast (F) planes showed 
multiple small intradural lumbar lesions along the cauda and conus medullaris. 
 
Figure 3: (A) The brain metastasis from Patient 1 comprises closely packed collections of 
small, monomorphic tumor cells compartmentalized by connective tissue septations.  
*Focally, the tumor elaborates a bluish, myxoid matrix (HE, x10). (B) Scattered tumor cells 
show vimentin immunoreactivity (x20) (C) Clusters of neoplastic cells immunolabel with 
cytokeratin (x20) (D) In some areas, the tumor within the uterus resembles the brain 
metastasis (HE, x20) (E) Malignant epithelial component of the brain metastasis from the 
second patient demonstrates a papillary architecture (HE, x20) and (F) stains with cytokeratin 
(x20). 
 
Table 1: Characteristics of MMMT cases presented in the literature and our new described 
two cases  
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